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At a Glance Commentary:  
Scientific Knowledge on the Subject 
Mesenchymal stromal cells (MSCs) are promising candidates for cell based therapy 
for the Acute Respiratory Distress Syndrome (ARDS). MSC-derived extracellular 
vesicles (EVs) have been shown to recapitulate many of the beneficial effects of 
MSCs in lung injury in vivo. These MSC-EVs have also been shown to transfer 
mitochondria to other cell types including macrophages, improving their 
bioenergetics. The effect of this EV-mediated mitochondrial transfer on macrophage 
function in the context of ARDS is currently unknown. 
What This Study Adds to the Field 
Human MSCs suppress pro-inflammatory cytokine secretion, enhance phagocytic 
capacity and promote M2 macrophage marker expression in human macrophages in 
the presence of bronchoalveolar lavage fluid from ARDS patients through paracrine 
mechanisms. These effects were mediated by mitochondrial transfer from MSCs to 
macrophages via EVs and were critically dependent on the enhancement of oxidative 
phosphorylation in macrophages. Moreover, adoptive transfer of murine alveolar 
macrophages (AMs) which had been pre-treated with MSC-EVs ex vivo mitigated 
endotoxin-induced lung injury in vivo. This study demonstrates an important role of 
MSC-EVs for MSC effects in ARDS, reveals a new mechanism of macrophage 
polarization and highlights the essential role of AMs as mediators of MSC therapeutic 
effects. 
 
This article has an online data supplement, which is accessible from this issue's table 
of content online at www.atsjournals.org 
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Abstract 
Rationale: Acute Respiratory Distress Syndrome (ARDS) remains a major cause of 
respiratory failure in critically ill patients. Mesenchymal Stromal Cells (MSCs) are a 
promising candidate for a cell based therapy. However, the mechanisms of MSCs 
effects in ARDS are not well understood. Here we focused on the paracrine effect of 
MSCs on macrophage polarization and the role of extracellular vesicle (EV)–
mediated mitochondrial transfer.  
Objectives: To determine the effects of human MSCs on macrophage function in the 
ARDS environment and to elucidate the mechanisms of these effects.  
Methods: Human monocyte-derived macrophages (MDMs) were studied in non-
contact co-culture with human MSCs when stimulated with lipopolysaccharide (LPS) 
or bronchoalveolar lavage fluid (BALF) from ARDS patients. Murine alveolar 
macrophages (AMs) were cultured ex vivo with/without human MSC-EVs before 
adoptive transfer to LPS-injured mice.  
Measurements and Main Results: MSCs suppressed cytokine production, increased 
M2 macrophage marker expression and augmented phagocytic capacity of human 
MDMs stimulated with LPS or ARDS BALF. These effects were partially mediated by 
CD44-expressing EVs. Adoptive transfer of AMs pre-treated with MSC-EVs reduced 
inflammation and lung injury in LPS-injured mice. Inhibition of oxidative 
phosphorylation in MDMs prevented the modulatory effects of MSCs. Generating 
dysfunctional mitochondria in MSCs using rhodamine-6G pre-treatment also 
abrogated these effects. 
Conclusions: In the ARDS environment, MSCs promote an anti-inflammatory and 
highly phagocytic macrophage phenotype through EV-mediated mitochondrial 
transfer. MSC-induced changes in macrophage phenotype critically depend on 
enhancement of macrophage oxidative phosphorylation. AMs treated with MSC-
derived EVs ameliorate lung injury in vivo. 
Word count: 244 
Keywords: acute respiratory distress syndrome; extracellular vesicles; mesenchymal 
stromal cells; macrophages; mitochondria
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Introduction 
Acute Respiratory Distress Syndrome (ARDS) is the leading cause of mortality and 
morbidity in the critically ill. While mortality rates have fallen with modifications in 
mechanical ventilation, they remain as high as 25-40% and no effective 
pharmacological treatments are available(1-3). ARDS results from multiple causes, 
pneumonia and sepsis being the most common and devastating. Uncontrolled 
alveolar inflammation is the hallmark of this disease. Alveolar macrophages (AMs) 
provide defence against respiratory pathogens and orchestrate inflammatory 
responses in the distal respiratory tract. Macrophages are polarized by environmental 
cues and adopt different phenotypes. M1 pro-inflammatory and M2 anti-inflammatory 
phenotypes are associated with the acute and resolving phases of inflammation in 
ARDS respectively(4, 5). Mesenchymal Stromal Cells (MSCs) are increasingly 
recognized as a promising candidate therapy for ARDS(6). We and others have 
reported that MSCs improve survival, reduce inflammation and enhance bacterial 
clearance in pre-clinical models of lung injury(7-14). Secretion of paracrine factors, 
modulation of host cells via secretion of extracellular vesicles (EVs) and 
mitochondrial transfer were shown to be important for the therapeutic effects of 
MSCs in these studies. These data have lent support to phase I/II clinical trials 
testing MSC administration to ARDS patients(15, 16). At present however, there are no 
potency assays in place to aid in the selection of MSC donors before their 
administration to patients(17) and despite rapid progression of MSCs to clinical trials, a 
complete understanding of the mechanisms of MSC immunomodulatory effects 
remains elusive. 
MSCs have the capacity to transfer mitochondria to alveolar epithelium enhancing 
bioenergetics and mitigating lung injury(9, 18). Our group previously demonstrated that 
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MSCs transfer mitochondria to human macrophages via tunnelling nanotubes which 
enhanced their phagocytic capacity and facilitated MSC antimicrobial effects in 
murine E. coli pneumonia(19). Importantly, depletion of AMs abrogated MSC 
protective effects in this model suggesting that AMs are key cellular mediators of 
MSC effects. While contact-dependent mechanisms such as these are important, a 
large body of evidence suggests that MSC therapeutic effects are mediated by 
paracrine factors(20-22). Recently EVs have emerged as an important component of 
the MSC secretory repertoire. MSC-EVs may contain a diverse cargo including 
proteins, mRNAs, miRNAs and mitochondria, the functional effects of which remain 
largely unknown(9, 23-25). MSC-derived EVs alone are capable of recapitulating many 
of the beneficial effects of MSC whole cell therapy(25-28). Phinney et al observed the 
transfer of MSC mitochondria and miRNAs via EVs to human macrophages in a 
model of silicosis and found that mitochondria enhanced macrophage bioenergetics 
while miRNAs suppressed Toll-like receptor signalling(24). They observed that 
normoxia (21% oxygen) induced oxidative stress thereby promoting mitophagy in 
MSCs. Ghanta et al then went on to demonstrate the importance of autophagy in 
maintaining healthy mitochondrial function and promoting survival in MSCs during 
oxidative stress(29). The influence of mitochondrial transfer on macrophage 
phenotype however, has not been studied extensively. Vats et al showed the 
importance of mitochondrial oxidative phosphorylation in the induction of IL-4-
induced anti-inflammatory M2 macrophage polarization(30). Indeed, glucose 
metabolism is intrinsically linked to macrophage activation state with M1 pro-
inflammatory macrophages utilizing glycolysis(31). In this study, we sought to 
characterize the effects of MSCs on human macrophage polarization in the in vitro 
models of ARDS. We tested the hypothesis that mitochondrial transfer from MSCs to 
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macrophages via EVs modulates macrophage function through promotion of 
oxidative phosphorylation. Some of the results of these studies have been previously 
reported in the form of an abstract(32-35). 
 
Methods 
See the online supplement for detailed methods. 
Human Bone Marrow-Derived Mesenchymal Stromal Cells (MSCs) 
MSCs were acquired from the Texas A&M Health Science Centre College of 
Medicine, Institute for Regenerative Medicine (Temple, Texas, USA), a National 
Institutes of Health repository. These cells fulfil all criteria set by the International 
Society of Cellular Therapy for definition of MSCs(36). Multiple MSC donors were used 
for experiment throughout this study. 
Human Monocyte-Derived Macrophage (MDM) and MSC Non-Contact Co-Culture 
Monocytes were isolated from donor buffy coats as previously described(37). Buffy 
coats were obtained from the Northern Ireland Blood Transfusion Service. Ethical 
approval was granted by the School Research Ethics Committee of Queen’s 
University Belfast. Monocytes were differentiated into macrophages for 7 days in the 
presence of 10ng/mL GM-CSF (R&D Systems). Macrophages were cultured with 
MSCs in the Transwell system at a ratio of 1:5 or with MSC conditioned medium 
(CM). Cells were stimulated with lipopolysaccharide (LPS) (Escherichia coli O111:B4, 
List Biological Laboratories) at 10ng/mL or 30% bronchoalveolar lavage fluid (BALF) 
pooled from nine patients with ARDS diluted in RPMI-1640 1% FBS for 24 or 72 
hours. Ethical approval for use of patient samples for research was obtained from the 
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Office for Research Ethics Committee Northern Ireland. In additional experiments, 
MSC-CM was pre-treated with CD44 neutralizing antibody (BD Biosciences) to 
assess the importance of EV uptake. 
Isolation of MSC-derived EVs 
MSC-EVs were isolated as previously described(27). Briefly, 15x106 cells were 
cultured in media supplemented with EV-depleted serum for 48 hours. CM was then 
collected and centrifuged at 10,000g for 20 mins to remove cells and debris, followed 
by centrifugation at 100,000g for 2 hours to isolate EVs. EVs were resuspended in 
2mL of media (7.5x106 cells/mL). Flow cytometry was used for characterization of 
EVs using the FACSCanto II flow cytometer and FACSDiva software. Analysis was 
performed using FlowJo v7 software. 
In vivo LPS-induced lung injury model 
C57BL/6 male mice (8- to 10-weeks old; Harland Institute, UK) were used. Animals 
were maintained in the Biological Services Unit at Queen’s University Belfast. 
Experiments were sanctioned and approved by the UK Home Office and Queen’s 
University Belfast Ethical Review Committee. Mice were anaesthetized by isoflurane 
inhalation and 20mg/kg of LPS was instilled intranasally. 4 hours after injury, AMs 
from ex vivo culture were given intranasally (2.5x105 AMs/mouse) following 
xylazine/ketamine anaesthetic. 24 hours after injury, mice were culled and BALF was 
taken for analysis. 
Mitochondrial transfer and functional studies 
For assessment of mitochondrial transfer MSC and MDM mitochondria were pre-
stained with MitoTracker® Deep Red and Green respectively (Thermofisher). CM 
was taken from pre-stained MSCs and added to MDMs for 24 hours to allow EV 
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uptake, mitochondrial transfer was visualized using the EVOS® FL Auto Imaging 
System (Life Technologies). For functional studies, MDM mitochondrial function was 
inhibited with oligomycin at 3µg/mL; MSC mitochondria were inhibited by pre-
treatment for 48 hours with 1µg/mL of rhodamine-6G (both Sigma Aldrich), which 
both target ATP synthase(38, 39). Mitochondrial respiration was assessed using the 
Seahorse XF Cell Mito Stress Test kit and XFe96 Extracellular Flux Analyzer. 
Analysis was performed using Wave v2.2 software (all Agilent Technologies). 
Statistical analysis 
Analysis was performed using GraphPad Prism 5 software. Experiments for each 
MDM donor were performed at least in triplicate; the average of three technical 
replicates were taken as a single data point for each donor and pooled together for 
statistical analysis. Pooled data were presented as the mean with standard deviation. 
For parametric data, Student’s t-test or one-way ANOVA with post-hoc analysis using 
Bonferroni’s selected comparisons was performed. For non-parametric data, Kruskal-
Wallis with post-hoc analysis using Dunn’s selected comparisons was used. 
Statistical significance was regarded as p<0.05.  
 
Results 
MSCs induce an unconventional M2-like phenotype in MDMs with increased 
phagocytic capacity in the presence of E. coli LPS 
LPS stimulation increased MDM secretion of pro-inflammatory cytokines TNF-α and 
IL-8. MSCs significantly diminished TNF-α and IL-8 production by 58±8% and 
30±15% respectively (Figure 1A, B). Table 1 summarizes the effects of MSC on 
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MDM production of cytokines and chemokines associated with M1 and M2 
macrophage polarization.  
The M1 cytokines IFNγ, IL-1β, IL-12p70 and IL-17 as well as the M2 anti-
inflammatory cytokine IL-10 were not detectable in these co-cultures. Levels of the 
M1 cytokines IL-23, the M1 chemokine CCL5, the M2 cytokine IL-1ra and the M2 
chemokine CCL17 were unaffected by MSCs. Levels of the M2 chemokines CCL18 
(68±21% reduction) and CCL22 (79±12% reduction) were also diminished with MSCs 
although the reduction in CCL18 levels was not significant. 
In this study we have investigated expression of an array of markers previously 
shown to be suitable for human macrophages (Table 2). Among those only 
expression of CD206 (marker for M2 polarization(40)) demonstrated differential 
regulation by LPS and MSC; MDM expression of CD206 was significantly increased 
by MSCs both in the presence (40±16% increase) or absence (25±12% increase) of 
LPS. (Figure 1C). Notably, expression of CD163 (an established M2 marker(41)) 
although detectable was not affected by any of the stimulations. MSCs significantly 
increased the proportion of phagocytic MDMs in the presence of LPS by 2.9-fold 
compared to LPS alone (Figure 1D). In contrast, fibroblasts cell control studies 
demonstrated that although fibroblasts diminished TNF-α secretion by MDMs, they 
did not influence IL-8 levels or CD206 expression, indicating that the observed 
effects were specific to MSC (Figure E1). 
MSCs modulate MDM phenotype and function in the BALF taken from ARDS 
patients  
To more closely mimic ARDS environment, MDMs were co-cultured with MSC in 30% 
BALF of ARDS patients or healthy volunteers. ARDS BALF resulted in a sharp up-
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regulation of TNF-α secretion which MSCs significantly reduced by 53±16% (Figure 
2A). MSCs reduced IL-8 levels in the presence of ARDS BALF, however this did not 
reach statistical significance (Figure E2). Consistently, MSCs were able to 
significantly increase the proportion of MDMs expressing the M2 marker CD206 
(Figure 2B). In the presence of ARDS BALF, MSCs were able to double the 
proportion of phagocytic MDMs (Figure 2C). 
MSC-derived EVs expressing CD44 are partially responsible for the MSC anti-
inflammatory effect and enhanced phagocytosis 
Flow cytometric analysis demonstrated that MSC-CM contains a population of 
particles of less than 4µm in diameter (herein referred to as EVs). This is consistent 
with the literature showing that MSC-EVs range from <100nm to 1000nm(24, 27). 
Further characterization demonstrated that EVs were >90% positive for MSC cell 
membrane, >90% negative for annexin V and propidium iodide staining, indicating 
minimal contamination with cell debris or apoptotic bodies and importantly EVs 
demonstrated uniform expression of CD44 (>98% positive)  (Figure 3A). 
Pre-incubation of MSC-CM with anti-CD44 antibody, but not with IgG, partially 
abrogated the effect on MDM TNF-α secretion (suppression of 70±19% reduced to 
43±15% after CD44 neutralization). Importantly, anti-CD44 antibody did not alter 
TNF-α secretion by MDMs without presence of MSC-CM (Figure 3B). As before, 
MSC-CM significantly increased MDM phagocytic activity in the presence of LPS. 
The percentage of phagocytic MDMs was increased by 28±5% and MDMs 
phagocytic index (determined by Median Fluorescent Intensity (MFI)) was increased 
9-fold, compare to LPS stimulation alone. Anti-CD44 but not IgG completely reversed 
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these effects. Antibodies given to MDMs in the absence of MSC-CM had no influence 
on phagocytic activity (Figure 3C).  
 
Adoptive transfer of murine AMs treated by MSC-EVs confer protection in LPS-
induced lung injury 
In order to test if modulation of macrophages by MSC-EVS has therapeutic effect in 
vivo, AMs were isolated from C57BL/6 mice, treated ex vivo with MSC-EVs for 48 
hours and adoptively transferred intranasally into mice which were challenged with 
LPS to induce lung injury. Intranasal instillation of LPS to mice resulted in lung injury 
at 24 hours as evidenced by increased inflammatory cell infiltration and protein 
content in the BALF. Treatment of mice with MSC-EV-treated AMs 4 hours after LPS 
challenge reduced total cell counts in the BALF by 45±13%, absolute neutrophil 
counts by 61±10%, BALF TNF-α levels by 40±15% and BALF protein by 52±6% 
compared to LPS-injured mice receiving vehicle control (Figure 4A). Importantly, 
treatment of mice with ex vivo-cultured AMs which were not treated with MSC-EVs 
had no effect (Figure 4B). Cytospin preparations of BALF demonstrate substantial 
inflammatory cell recruitment to the alveolar compartment consisting predominantly 
of neutrophils in the LPS-injured group which is reduced by administration of EV-
treated AMs (Figure 4C). 
MSC-EVs transfer functional mitochondria to MDMs enhancing macrophage 
oxidative phosphorylation 
Flow cytometric analysis of MSC-CM demonstrates that 25% of MSC-EVs detectable 
by this method are positive for mitochondria (Figure 5A). Mitochondrial transfer from 
MSCs to MDMs was visualized by fluorescence microscopy. MSCs were pre-stained 
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with MitoTracker® Red FM, CM collected and added to MDMs which had been pre-
stained with MitoTracker® Green FM and Hoechst nuclear stain (blue). At 24 hours, 
there is evidence of MSC mitochondria-containing EVs adhering to the MDMs (red 
staining, white arrows) and co-localization of MSC mitochondria into the MDM 
mitochondrial network (yellow staining, yellow arrow) (Figure 5B).  
To specifically inhibit mitochondrial respiration in MSCs, MSCs were pre-treated with 
rhodamine-6G which irreversibly binds to ATP synthase(38). Rhodamine treatment 
abrogated MSC mitochondrial respiration while enhancing non-mitochondrial 
respiration (Figure E3, A); importantly the capacity of MSCs to secrete paracrine 
factors (Ang-1, IL-8) was not significantly affected (Figure E3, B, C), ruling out non-
specific effects of rhodamine on MSC capacity to secrete soluble factors. Rhodamine 
did not induce cell death in MSCs after 48h (Figure E3, D). MSC-CM enhanced 
mitochondrial respiration capacity in MDMs compared to MDMs stimulated with LPS 
alone. CM from rhodamine pre-treated MSCs had no effect on these parameters 
(Figure 5C).  
Transfer of mitochondria-containing MSC-EVs is responsible for MSC modulation of 
MDMs through enhanced oxidative phosphorylation 
The ATP synthase inhibitor oligomycin drastically increased the MDM TNF-α 
response to LPS (3.8-fold). Oligomycin treatment had no cytotoxic effects on MDMs 
after 24 hours (Figure E4). Importantly, the addition of oligomycin completely 
prevented the anti-inflammatory effect of MSC-CM (Figure 6A). Similarly, oligomycin 
completely reversed the effect of MSC-CM on MDM phagocytosis (Figure 6B). 
These results provide evidence for direct involvement of mitochondrial oxidative 
metabolism in MSC-CM-mediated modulation of macrophage function. CM from 
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MSCs pre-treated with rhodamine-6G lose the capacity to reduce LPS-induced TNF-
α production, enhance the phagocytic capacity of MDMs and upregulate expression 
of M2 marker CD206 (Figure 6C-E). In aggregate, these data demonstrate that 
MSCs modulate primary human macrophages through EV-mediated transfer of 
functional mitochondria which enhance macrophage oxidative phosphorylation. 
 
Discussion 
The following conclusions can be drawn from this study: 1) MSCs reprogram human 
macrophages in the presence of E. coli LPS and ARDS patient BALF via paracrine 
mechanisms; the MSC-induced macrophage phenotype is characterized by a 
dampened inflammatory cytokine secretory profile, increased expression of the M2 
marker CD206 and enhanced phagocytic capacity (Figures 1 and 2); 2) MSC-EVs 
expressing CD44 are partially responsible for the suppression of MDM TNF-α 
production and promoting phagocytosis (Figure 3); 3) MSC-EV-treated murine AMs 
protect from endotoxin-induced lung injury in vivo (Figure 4); 4) the transfer of 
functional mitochondria in EVs is responsible for MSC anti-inflammatory and 
phagocytosis enhancing effects on macrophages in the inflammatory environment 
through the promotion of oxidative phosphorylation (Figures 5, 6). 
Phinney et al previously showed that MSCs donate their mitochondria to human 
macrophages under oxidative stress via EV-mediated transport thereby enhancing 
their bioenergetics(24). Our group has recently shown that mitochondrial transport via 
tunnelling nanotubes from MSCs to MDMs was important for enhancing phagocytic 
capacity(19). The current study shows for the first time that the transfer of 
mitochondria via MSC-EVs promotes phagocytosis and suppresses pro-inflammatory 
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cytokine secretion by human macrophages. This mitochondrial transfer was 
associated with increased oxidative phosphorylation in MDMs which was necessary 
for these modulatory effects. Moreover, this work demonstrates that modulation of 
AMs by MSC-derived EVs is sufficient to mitigate lung injury in vivo. 
We first sought to characterize human macrophage modulation by MSC in the in vitro 
models of inflammation investigating cytokine and chemokine secretion, expression 
of characteristic surface markers and phagocytic activity. MSCs were able to reduce 
MDM production of two major pro-inflammatory cytokines associated with ARDS 
severity TNF-α and IL-8(42, 43) in the presence of E. coli LPS (Figure 1A, B). This 
corroborates previous reports showing that MSCs are able to suppress secretion of 
pro-inflammatory cytokines by macrophages(40). Other tested M1 and M2-associated 
cytokines and chemokines were undetectable or unaffected by MSCs although the 
M2 chemokine CCL22 was reduced (Table 1). Notably, IL-10 was not detectable in 
these cultures; this is in controversy with a number of reports describing upregulation 
of IL-10 production by macrophages that are cultured with MSCs(40, 44). This 
discrepancy may be explained by the inherent variability of the immunoregulatory 
capacity of MSC donors. Moreover, macrophages differentiated in GM-CSF, like in 
the present study, have been shown to express low levels of IL-10 after LPS 
treatment(45).  
MSCs consistently upregulated expression of the key M2 macrophage marker 
CD206 in the presence of LPS, while other markers of M1 and M2 macrophages 
were unaffected (Figure 1C and Table 2). This is in agreement with previous reports 
describing MSC induction of M2-type macrophages characterized by CD206 
expression(40, 46). The lack of effect on other M1/M2 markers is perhaps a reflection of 
the lack of well-defined markers to unambiguously define human macrophage 
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activation state(47). It could also be explained by the different methods for monocyte 
differentiation and macrophage stimulation; in our studies we used GM-CSF as a 
differentiation factor to model AMs(48, 49). GM-CSF also promotes an M1-like 
phenotype, more closely mimicking activated AMs which would be present in the 
alveoli of ARDS patients. MSCs were able to increase the proportion of phagocytic 
MDMs in the presence of LPS (Figure 1D). This adds to the body of literature 
supporting the phagocytosis enhancing effects of MSCs on both macrophages and 
monocytes(8, 10, 19, 27).  
This study demonstrates for the first time that MSCs are capable of modulating MDM 
phenotype and function in the presence of BALF taken from ARDS patients. MSCs 
were able to reduce TNF-α secretion, increase CD206 expression and promote 
phagocytosis in MDMs exposed to ARDS BALF (Figure 2), effectively mimicking the 
distal lung microenvironment of these patients. Induction of a less pro-inflammatory 
AM which exhibits increased phagocytic capacity may improve outcomes in ARDS 
which is classically associated with a rampant inflammatory response and substantial 
bacterial burden such as sepsis or pneumonia-induced ARDS(1). These data add 
valuable clinical relevance to these in vitro studies. Importantly, we have shown 
previously that MSCs are able to migrate into the alveolar spaces even when given 
intravenously(19), therefore it is plausible that MSC may produce similar effects on 
AMs of patients. Additionally, the capacity of MSCs to induce polarization towards 
M2-type monocytes/macrophages, identified by CD206 expression, may serve as a 
biomarker for MSC efficacy in clinical samples. EVs have emerged as a major 
contributor to the therapeutic effects of MSCs in lung injury, capable of recapitulating 
many of the effects of the whole cell therapy(25-27). CD44 expression on MSC-EVs 
was shown to be necessary for their uptake and therapeutic effect on target cells(27, 
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50). In the current study, prevention of EV uptake by MDMs using anti-CD44 
neutralizing antibody abrogated the ability of MSC-CM to reduce MDM TNF-α 
secretion and enhance phagocytosis (Figure 3B, C). This suggests that MSC-EVs 
are primarily responsible for MSC modulation of MDM function. 
To confirm the importance of MSC-EV uptake by AMs in lung injury in vivo, 
endotoxin-injured mice were given murine AMs, pre-treated with MSC-EVs ex vivo. 
AMs exposed to MSC-EVs but not untreated AMs were able to significantly reduce 
the extent of lung injury after 24 hours, demonstrated by reduced inflammatory cell 
recruitment and decreased BALF protein levels (Figure 4). These data corroborate 
our previous findings where clodronate-based depletion of AMs abrogated the 
beneficial effects of MSCs in lung injury in vivo, demonstrating that AMs are cellular 
mediators of the MSC effect(19). Importantly, these new data not only highlight AMs 
as key cellular targets of MSC-EVs but also emphasize an essential role of AMs in 
mitigating lung injury. This is the first study to report the efficacy of adoptive transfer 
of AMs in endotoxin-induced lung injury. Adoptive transfer of macrophages has also 
been investigated in colitis and airway hyper-responsiveness with promising 
results(51, 52). While not true AMs, Litvack et al have also shown that stem cell-derived 
alveolar-like macrophages improve bacterial and neutrophil clearance in another 
model of lung injury(49) but further study is required to determine the safety and 
feasibility of these treatment modalities. Moreover, these data contribute to the 
growing body of literature which suggests the potential of MSC-EVs as a therapy in 
place of MSCs(25-27). While there have been no reports of MSC-induced neoplasia to 
date, EVs cannot themselves transform to form tumours reducing the potential risk 
associated with cell-based therapy. It has been shown that different methods of 
isolation can influence vesicle yield, purity and contents(53). Obtaining a sufficient 
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quantity of EVs from MSCs for their effective use in the clinic also presents a 
significant challenge; a consensus must be reached on the optimal culture conditions 
and EV isolation protocols to standardize this process. 
Our group and others have previously shown the transfer of mitochondria from MSCs 
to human macrophages via EVs(19, 24). In this study, MSC-EV-mediated mitochondrial 
transport to MDMs was visualized with fluorescence microscopy (Figure 5B). The 
treatment of MDMs with MSC-CM resulted in enhanced bioenergetics in the 
macrophages evidenced by increased basal mitochondrial respiration as well as ATP 
turnover. MSC-CM taken from rhodamine-6G-pre-treated MSCs with dysfunctional 
mitochondria were unable to affect these parameters (Figure 5C). These findings are 
in line with previous reports of improved bioenergetics in cells receiving MSC 
mitochondria including macrophages, alveolar epithelial cells and vascular 
endothelial cells(9, 18, 19, 24, 54). To confirm that production of soluble mediators was 
sustained in rhodamine-6G-treated MSCs, angiopoietin-1 and IL-8 levels were 
quantified after LPS treatment with or without rhodamine-6G pre-treatment. While 
diminished, these paracrine factors were still produced at high levels suggesting that 
paracrine secretion by MSCs was not greatly affected by inhibition of their 
mitochondrial function (Figure E3, B, C). 
M1 pro-inflammatory macrophages have been shown to utilize glycolytic 
metabolism(31). Vats et al highlighted the importance of mitochondrial oxidative 
phosphorylation in the induction of M2-type macrophages through IL-4 signalling. 
They observed that mitochondrial inhibition in macrophages blocked the anti-
inflammatory effects of IL-4(30). In the present study, addition of the mitochondrial 
inhibitor oligomycin prevented the suppression of TNF-α and the enhancement of 
phagocytosis in macrophages by MSC-CM, demonstrating that the MSC effect is 
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critically dependent on oxidative phosphorylation (Figure 6A, B). We hypothesized 
that mitochondrial transfer via MSC-EVs was responsible for both enhancing MDM 
phagocytosis and suppressing pro-inflammatory cytokine production through the 
promotion of oxidative phosphorylation. Indeed, MSC-CM taken from rhodamine-6G-
pre-treated-MSCs with dysfunctional mitochondria had no effect on TNF-α 
production, phagocytosis or CD206 expression in LPS-treated MDMs (Figure 6C-E).  
There are limitations to this study. The BALF experiments used ARDS BALF diluted 
to 30% by volume; while exposing the MDMs to all of the constituents of the ARDS 
microenvironment, this will effectively reduce the concentrations of the stimuli it 
contains. The endotoxin-induced lung injury model was relatively mild(14, 25), however 
the primary aim of the in vivo experiments was to provide a proof of principle that 
AMs are important cellular mediators of MSC-EV effects using a gain-of-function 
approach. Additionally, we did not investigate the mechanisms by which MSC-EV-
treated murine AMs are protective in lung injury. 
In conclusion, this study demonstrates that in the inflammatory environment of 
ARDS, MSCs modulate human macrophages towards decreased production of pro-
inflammatory cytokines, increased expression of the M2 phenotype marker CD206 
and enhanced phagocytic capacity. MSC-EVs carrying mitochondria are responsible 
for these effects through the promotion of oxidative phosphorylation in macrophages, 
uncovering a novel mechanism of modulation of macrophage polarization. Moreover, 
this work suggests that changes in AMs induced by MSC-derived EVs are sufficient 
to elicit protection in lung injury in vivo. The ability of MSCs to promote CD206 
expression in human macrophages may serve as a biomarker of MSC efficacy in 
ARDS patients. 
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Figure legends 
Figure 1. Human mesenchymal stromal cell (MSC) modulation of human monocyte-
derived macrophage (MDM) phenotype and function. (A) MSCs in non-contact co-
culture reduce the production of TNF-α by MDMs after 24h of lipopolysaccharide 
(LPS) treatment. One-way ANOVA with Bonferroni’s post-hoc test (n=5 per group). 
(B) IL-8 production by MDMs was reduced by MSC co-culture after LPS treatment. 
One-way ANOVA with Bonferroni’s post-hoc test (n=4 per group). (C) MSC co-culture 
increases the percentage of MDMs expressing CD206 on their surface in the 
absence (i) or presence (ii) of LPS. Unpaired t-test (n=3 per group) and one-way 
ANOVA with Bonferroni’s post-hoc test (n=4 per group) respectively. (D) MSCs 
increase the proportion of MDMs which had phagocytosed E. coli pHrodo® 
fluorescent BioParticles® after LPS. One-way ANOVA with Bonferroni’s post-hoc test 
(n=5 per group). Data are presented as mean ± standard deviation. *p<0.05, 
**p<0.01.  
 
Figure 2. Human mesenchymal stromal cells (MSCs) modulate human monocyte-
derived macrophages (MDMs) in the presence of Acute Respiratory Distress 
Syndrome (ARDS) patient broncholaveolar lavage fluid (BALF). (A) MSCs reduce the 
production of TNF-α by MDMs treated with 30% ARDS BALF for 24 hours. Kruskal-
Wallis with Dunn’s post hoc test (HV BALF n=3, other groups n=5). (B) MSCs 
increase the proportion of MDMs expressing the M2 macrophage surface marker 
CD206 after 72 hours. One-way ANOVA with Bonferroni’s post-hoc test (n=3 all 
groups). (C) MSCs increase the proportion of phagocytic MDMs in the presence of 
ARDS BALF. One-way ANOVA with Bonferroni’s post-hoc test (n=4 all groups). Data 
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are presented as mean ± standard deviation. *p<0.05, **p<0.01. HV BALF - healthy 
volunteer BALF, BALF - ARDS BALF. 
 
Figure 3. CD44-expressing extracellular vesicles (EVs) from human mesenchymal 
stromal cells (MSCs) are partially responsible for their modulatory effects. Flow 
cytometry demonstrates that (A)(i) MSC-derived EVs are smaller in diameter than 
latex beads of 4µm diameter and (ii) are positive for CD44 expression on their 
surface. (B) Pre-incubation of MSC-CM with anti-CD44 neutralizing antibody partially 
reversed MSC suppression of TNF-α secretion by MDMs (n=4 all groups) and 
completely prevented MSC enhancement of (C)(i) the proportion of phagocytic 
MDMs as well as (ii) their phagocytic index (n=5 all groups). One-way ANOVA with 
Bonferroni’s post-hoc test. Data are presented as mean ± standard deviation. 
*p<0.05, **p<0.01. 
 
Figure 4. Human mesenchymal stromal cell (MSC) extracellular vesicle (EV)-treated 
alveolar macrophages (AMs) reduce lipopolysaccharide (LPS)-induced lung injury. 
Treatment of LPS-injured mice with EV-treated AMs reduced total cell counts and 
neutrophilic cell counts as well as the amount of TNF-α and protein (A) in the 
bronchoalveolar lavage fluid (BALF). One-way ANOVA with Bonferroni’s post-hoc 
test (A, B and D - n=4 PBS, n=5 LPS, n=3 LPS+EV-AM). Student’s unpaired t-test (C 
- n=3 LPS, n=3 LPS+EV-AM). Untreated AMs had no effect on total or neutrophil cell 
counts and had no effect on BALF TNF-α or protein levels (B). One-way ANOVA with 
Bonferroni’s post-hoc test (F, G and I - n=4 PBS, n=4 LPS, n=5 LPS+unt-AM). 
Student’s unpaired t-test (H - n=5 LPS, n=5 LPS+unt-AM). Cytospins of BALF 
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preparations demonstrate inflammatory cell recruitment to the airspaces after LPS 
injury and the reduced cell numbers after treatment with EV-treated AMs but not 
untreated AMs (images taken at 20x magnification) (E). Data are presented as mean 
± standard deviation. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 5. Human mesenchymal stromal cell (MSC)-derived extracellular vesicles 
(EVs) transfer functional mitochondria to human monocyte-derived macrophages 
(MDMs) which enhances macrophage oxidative phosphorylation. (A) Flow cytometry 
of culture medium taken from MitoTracker® Red pre-stained MSCs shows that 25% 
of EVs are positive for mitochondria. (B) EVs contained in MSC culture medium (CM) 
transfer mitochondria (red) to MDMs (MitoTracker® Green) (white arrows). MSC 
mitochondria are integrated into the MDM mitochondrial network (yellow, yellow 
arrows) (images at 20x magnification). (C) Treatment of MDMs with MSC-CM 
resulted in an increase in basal mitochondrial respiration (i) as well as mitochondrial 
ATP turnover (iii) determined by the Seahorse metabolic analyzer. The increase in 
maximal mitochondrial respiration did not reach statistical significance (ii). Kruskal-
Wallis with Dunn’s post-hoc test (n=4 all groups). Data are presented as mean ± 
standard deviation. *p<0.05. OCR - oxygen consumption rate. 
 
Figure 6. Mitochondrial transfer via human mesenchymal stromal cell (MSC)-derived 
extracellular vesicles (EVs) modulates human monocyte-derived macrophage (MDM) 
function through enhancement of macrophage oxidative phosphorylation. (A) 
Addition of oligomycin (reversible ATP synthase inhibitor) prevented the suppression 
of TNF-α by MSC culture medium (CM) (n=5 all groups but DMSO n=4). (B) 
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Oligomycin also prevented MSC-CM enhancement of the proportion of phagocytic 
MDMs (i) and phagocytic index (ii) (n=7 all groups). Pre-treatment of MSCs with 
rhodamine-6G (irreversible ATP synthase inhibitor) similarly reversed MSC-CM 
capacity to suppress TNF-α production (C) (n=4 all groups), enhance the phagocytic 
capacity of MDMs (D) (n=4 all groups) as well as promoting M2 marker CD206 
expression (E) (n=5 all groups). All one-way ANOVA with Bonferroni’s post-hoc test. 
Data are presented as mean ± standard deviation. *p<0.05, **p<0.01, ***p<0.001. 
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MATERIALS AND METHODS 
Culture of human bone marrow-derived MSCs 
Bone marrow-derived MSCs were provided by the Texas A&M Health Science 
Center College of Medicine Institute for Regenerative Medicine at Scott & White 
through a grant from NCRR of the National Institute of Health (NIH), Grant # 
P40RR017447. These MSCs were extensively characterized by the supplier 
testing for plastic adherence, expression of key mesenchymal markers and 
absence of haematopoietic markers, as well as differentiation capacity for a 
number of mesenchymal lineages. These assessments fulfil the criteria put 
forward by the International Society for Cellular Therapy for characterization and 
identification of MSCs. MSCs were cultured under standard tissue culture 
conditions; 37ºC, 5% CO2 and 21% O2. MSCs were grown in T175 culture flasks 
using α-Minimal Essential Medium (α-MEM) supplemented with 16.5% heat-
inactivated foetal bovine serum (FBS), 1% L-glutamine and 50µg/mL penicillin-
streptomycin (PS) (all from Gibco, Thermofisher) and fed every three days. 20mL 
of media was used to ensure complete coverage of the T175 flask. MSCs were 
grown to 70% confluence before being passaged. MSCs were lifted from culture 
by first aspirating the media, washing once with deionised PBS (DPBS) and 
adding trypsin-EDTA (both from Gibco, Thermofisher) diluted in DPBS to a 
concentration of 0.05% for 3-4 minutes at 37ºC and 5% CO2. The flasks were then 
tapped forcefully to encourage detachment. Once detached, an equal volume of 
α-MEM16.5%FBS+PS was added to neutralize the trypsin. The cell solution was then 
centrifuged at 1200rpm for 5 mins and the supernatant aspirated. The pellet was 
resuspended in a volume of media equating to 1mL of α-MEM16.5%FBS+PS per T175 
flask of cells before performing a cell count. 
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Cryovials containing 1 million MSCs were taken from liquid nitrogen storage and 
quickly thawed at 37ºC in a water bath for 2 minutes. The 1mL cell suspension 
was then added to 10mL of pre-warmed α-MEM16.5%FBS+PS. The cells were 
centrifuged at 1200rpm for 5 mins and the supernatant was decanted off, 
removing the dimethylsulfoxide (DMSO) (Sigma Aldrich). The pellet was 
resuspended in 1mL of media before being added to a pre-warmed T175 flask 
and returned to the incubator. If the MSCs were for expansion, before 24 hours 
the MSCs were lifted using trypsin as described earlier, counted and seeded 
across T175 flasks at a cell density of 60 cells/cm2. When the cells reached 70% 
confluence they were detached, pooled, counted and diluted in media to a 
concentration of 2 million cells/mL. The cell solution was then diluted 1:1 using 
freezing medium consisting of α-MEM50%FBS+PS and DMSO at a ratio of 9:1, 
bringing the cell concentration to 1 million cells/mL. 1mL of the cell 
solution/freezing solution mixture was then added to each cryovial, placed in a 
freezing container filled with isopropanol and stored overnight at -80ºC. The next 
morning the cryovials are transferred to liquid nitrogen for long term storage. 
 
Human monocyte-derived macrophage (MDM) culture 
Buffy coats from single donors were obtained from the Northern Ireland Blood 
Transfusion Service (NIBTS); these buffy coats are what remains after blood 
donations are processed to extract the majority of the red cell fraction. Ethical 
approval for the use of these buffy coats was acquired through the Queen’s 
University Belfast Research Ethics Committee (Ref: 14/35 Title: Investigating 
regulation of inflammation and repair in the Acute Respiratory Distress Syndrome 
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using blood cells extracted from buffy coat). This leaves a white cell enriched 
sample, which is depleted of platelets and a large proportion of red cells. Diluted 
the buffy coat (approximately 40-65mL) in Hank’s Balanced Salt Solution (HBSS) 
minus Ca2+ and Mg2+ (Gibco, Thermofisher) up to a volume of 140mL. Added 
15mL of Ficoll Paque Premium (GE Healthcare) to a 50mL falcon tube and then 
slowly layered the blood mixture on top at a 45ᵒ angle, being careful not to mix the 
two layers, to produce four 50mL falcons. Centrifuged at 480g for 20 minutes at 
20ºC with the brakes off. This separates the blood components by density 
centrifugation and produces a white layer containing lymphocytes and monocytes. 
Used a Pasteur pipette to extract the white cell layer from the tubes taking care 
not to remove red cells. Pooled the cells from each tube into one falcon before 
adding HBSS up to 50mL. Centrifuged at 1200rpm for 5 minutes at 4ᵒC. Aspirated 
the supernatant, taking care not to lose the cell pellet. This is done to remove any 
residual Ficoll that would have been extracted along with the cells. Repeated the 
wash step with HBSS two more times. Resuspended the cell pellet in 20mL of 
Roswell Park Memorial Institute (RPMI) (Gibco, Thermofisher) media 
supplemented with 1% heat-inactivated FBS and 50µg/mL penicillin-streptomycin 
and prepared an aliquot with a 10x dilution of cells in media. Added 20uL of this to 
a haemocytometer and place in the incubator for 5 minutes to allow monocytes to 
adhere. Performed a cell count using a light microscope and haemocytometer, 
adherent monocytes will appear cloudy/translucent. Seeded the monocytes at the 
desired density in RPMI1%FBS+PS for at least 2 hours to allow adherence of the 
monocytes. All other contaminating cells, e.g. erythrocytes and lymphocytes, will 
not adhere. Monocytes were seeded at 300,000 per well in 24-well plates and 
1,000,000 per well in 6-well plates. Aspirated the RPMI1%FBS+PS from the adherent 
Page 41 of 66  AJRCCM Articles in Press. Published on 09-June-2017 as 10.1164/rccm.201701-0170OC 
 Copyright © 2017 by the American Thoracic Society 
  
E5 
 
monocytes and washed twice with HBSS to remove contaminating cells. Added 
RPMI10%FBS+PS further supplemented with 10ng/mL of GM-CSF (R&D Systems, 
Biotechne). GM-CSF will differentiate the monocytes into macrophages over the 6 
to 7-day incubation.  
 
Non-contact co-culture of human MSCs and human MDMs 
After 6-7 days of differentiation MDM co-culture with MSCs could begin. Before 
beginning the experiment, MDMs were serum starved in unsupplemented RPMI 
for 2 hours. MSCs used in experiments were passage 3-5. MSCs would be 
suspended in culture above the MDMs using 0.4µm porous hanging cell culture 
transwell inserts (Merck Millipore). These required pre-soaking in media for at 
least 20 mins prior to adding the cells to facilitate cell adherence and to allow co-
culture without contact. For all co-culture experiments, MSCs were prepared at a 
5:1 ratio of MDMs to MSCs. Conditions were prepared in RPMI1%FBS+PS with any 
additional stimuli at a volume of 500µL for 24-well plates and 2mL for 6-well 
plates.  
 
In vitro stimulation experiments 
To generate an inflammatory environment, E. coli LPS O111:B4 (List Biological 
Laboratories) was added to the MDMs and MSCs at a working concentration of 
10ng/mL in RPMI1%FBS+PS. In later experiments, to mimic the microenvironment of 
the alveolar compartment of patients with ARDS, BALF from ARDS patients was 
used for stimulation in place of LPS. These BALF samples were those taken from 
the clinical trial performed by Craig et al and published in 2011, where they 
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investigated the use of simvastatin as a treatment for ARDS(394). BALF samples 
used for these stimulation experiments were baseline samples taken prior to any 
intervention. BALF from nine of these patients were pooled to generate a stock 
and the pooled sample was then diluted to 30% in RPMI1%FBS+PS before 
stimulation. When possible healthy volunteer BALF was included to demonstrate 
whether it is ARDS patient BALF or BALF in general that is responsible for the 
observed effects. Healthy volunteer samples were taken from the study published 
by Shyamsundar et al in 2014 investigating the effects of KGF in mild, LPS-
induced lung injury(395). The healthy volunteer BALF samples used for these 
stimulations were from individuals who had received neither LPS nor KGF.  
 
Enzyme-linked Immunosorbent Assay (ELISA)  
Human TNF-α and IL-8 levels in cell supernatants were quantified using ELISA 
duoset kits (R&D Systems, Biotechne). Exact working concentrations of the kits 
constituents may be found in the manufacturer’s instructions. Capture antibody for 
the cytokine of interest was prepared in 1xPBS (Gibco, Thermofisher) to the 
desired concentration and 100µL of this solution was added to each well of a 
Maxisorp 96-well ELISA plate (Nunc). The plate was then sealed and incubated 
overnight at room temperature. The capture antibody was aspirated and the wells 
washed using wash buffer (1xPBS with 0.05% Tween-20 (Sigma Aldrich)) three 
times, blotting against clean paper towels after each wash. Care was taken to 
remove as much liquid as possible after the final wash when blotting. Non-specific 
binding was prevented by blocking the plates with 300µL of reagent diluent per 
well (1xPBS with 1% bovine serum albumin (BSA) (Sigma Aldrich)) for at least 1 
Page 43 of 66  AJRCCM Articles in Press. Published on 09-June-2017 as 10.1164/rccm.201701-0170OC 
 Copyright © 2017 by the American Thoracic Society 
  
E7 
 
hour. Again, the plates were washed three times with wash buffer and blotted 
before addition of the cytokine standards and supernatant samples. A two-fold 
dilution series was used to prepare a range of standard concentrations and then 
100µL of these and the samples were added to each well for a 2 hour incubation. 
The wells were washed three times and 100µL of detection antibody prepared in 
reagent diluent was added for another 2 hour incubation. After another three 
washes, 100µL of streptavidin-horse radish peroxidase diluted 1:40 in reagent 
diluent was added to each well, and incubated for 20 mins protected from light. A 
final three washes was performed and 100µL of 3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate solution (Life technologies) was added and incubated for 20 
mins, or until the standards had suitably developed, protected from light. 50µL of 
2M sulphuric acid stop solution was added to each well and the plate gently 
tapped to ensure mixing. The ELISA was then immediately analyzed using the 
Versamax spectrophotometer set to read at 450nm and 540nm wavelength. A 
subtraction of the wavelength absorbance readings at 540nm was taken from the 
readings at 450nm for correction. 4-parameter standard curves were produced 
using Softmax Pro v2.6 and concentrations of samples were extrapolated.  
 
Bioplex 
The measurement of multiple other cytokines and chemokines was performed 
using a custom Luminex Performance Assay Multiplex kit (R&D Systems, 
Biotechne). The analytes for this assay were the cytokines IL-1β, IL-1ra, IL-10, IL-
12, IL-23 and IFNγ and the chemokines CCL5, CCL17, CCL18 and CCL22. The 
assay was performed according to manufacturer’s instructions. The kit was used 
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along with a Luminex analyzer that uses a dual laser flow-based sorting and 
detection platform. Each analyte’s antibody is provided already coated onto 
coloured microparticles. Standards are provided for the analytes and a 3-fold 
dilution series is used to generate a range. 50µL of either the 
standard/microparticle or sample/microparticle mixtures were added to the plate 
provided. The plate was then incubated at room temperature for 3 hours with 
gentle agitation on a shaker before washing with 100µL of the wash buffer 
provided with the kit. Wash buffer was then removed with a vacuum manifold 
dispenser which siphons the liquid through filters on the base of the plate. This 
wash step was repeated two more times. 50µL of streptavidin-phycoerythrin was 
added to each well and incubated for 30 mins protected from light on a shaker. 
Three more washes were performed and a fourth wash was allowed to sit for two 
minutes before aspiration. There are lasers present in the apparatus which are 
specific to each of the colour-coded microparticles which should be conjugated to 
the antibody-analyte complexes. Another laser will excite any of the streptavidin-
phycoerythrin fluorophore which has now bound and is present in levels 
proportional to the amount of analyte in the samples. The plate is then analyzed 
and sample analyte concentrations were deduced by plotting the standard 
concentrations against the median fluorescence intensity (MFI) using a 5-
parameter logistic fit. 
 
Flow cytometry 
Flow cytometry was used for analysis of macrophage surface markers, 
phagocytosis assays and EV characterization. After the experimental time point 
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was reached inserts and supernatants were removed from the MDMs and the 
cells were washed with PBS. 1mL of flow buffer (PBS 5%FBS) was added to the 
cells and they were gently scraped from the well plates using a cell scraper. The 
cell solution was then added to 5mL polystyrene flow tubes (Sarstedt, Fisher 
Scientific) and centrifuged at 350g for 5 mins at 4ᵒC to pellet the cells. The tubes 
were then decanted to remove the flow buffer, leaving 200µL in the tube. The cells 
were resuspended in 0.5mL of flow buffer and 20µL of human FcR binding 
inhibitor (eBioscience) was added. The cells were incubated on ice for 20 mins to 
block non-specific binding. Following this, the antibodies (see Table E1) would be 
added at the necessary dilution and incubated for 30 mins on ice, protected from 
light. For each experiment a number of controls were included, an unstained 
control, isotypes for each fluorophore in use and single stain controls for each 
fluorophore. For experimental groups, all antibodies of interest were added to 
each tube. After the antibody incubation, 3mL of flow buffer was added to each 
tube and the cells were centrifuged at the same settings as earlier. The 
supernatant was aspirated and the wash step repeated. After the second wash, 
200µL was left in each flow tube and the samples were run. Samples were 
processed using the FACSCantoII flow cytometer and FACSDiva software (BD 
Biosciences). Where necessary, compensation between fluorophores was 
performed on the FACSDiva software by using single stain controls. Data was 
then analyzed using FlowJo v7 software (Treestar).  
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Table E1: Antibodies used for macrophage markers 
       Cell surface marker Fluorochrome 
conjugate 
Manufacturer 
       Anti-human CD40 FITC eBioscience 
       Anti-human CD54 PE eBioscience 
       Anti-human CD163 APC eBioscience        
       Anti-human CD206 PE-Cyanine7 eBioscience        
 
Flow cytometric phagocytosis assay 
To determine the phagocytic capacity of MDMs with or without co-culture of 
MSCs, fluorescently labelled pHrodo® green E. coli BioParticles® (Thermofisher) 
were used. Briefly, after 24 hours of co-culture, the supernatant is removed and 
the MDMs are washed twice with PBS. E. coli particles were then suspended in 
RPMI1%FBS+PS with 10µL of stock per 1mL of media (provides particles at a 20:1 
ratio particles to MDMs). E. coli bioparticles were then added to MDMs in a total 
volume of 2mL for 6-well plates. The plates were then centrifuged at 350g for 5 
mins at 4ºC to ensure contact between the MDMs and the particles. MDMs were 
incubated at 37ºC and 5%CO2 for 90 minutes, protected from light, to allow 
phagocytosis to occur. A number of wells are not treated with particles and serve 
as an unstained control. As recommended by the manufacturer, a number of wells 
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were treated with the particles but incubated on ice as a control. These cells 
should not be capable of phagocytosis and any signals detected in these wells 
should be subtracted as background. After the incubation, the supernatant was 
aspirated, and the cells were washed twice in PBS. A final 1mL of PBS was added 
to each well and the MDMs are gently scraped. The cell solution was centrifuged 
at 350g 4ºC for 5 mins and the supernatant aspirated before adding 200µL of PBS 
to the tube for resuspension. The samples were then analyzed by flow cytometry. 
 
CD44 blockage experiments 
To determine if MSC-EVs were responsible for MSC effects on MDMs, blockage 
studies were performed. MSC-CM was generated and treated with an antibody for 
human CD44 (mouse anti-human CD44, BD Biosciences) or isotype control 
(mouse IgG2B, R&D Systems, Biotechne) to a final concentration of 3µg/mL or 
given no antibody. They were incubated for 30mins at 37ᵒC with gentle mixing to 
allow the antibody to bind any EVs present in the CM and then added on to serum 
starved MDMs with 10ng/mL of LPS as described earlier. Importantly CD44 is also 
expressed on macrophages, so in order to control for any effects of this antibody 
on MDMs directly, additional groups were included where MDMs were treated with 
the antibodies without MSC-CM. After 24 hours of stimulation, supernatants were 
extracted for cytokine analysis. 
 
Generation of EV-free FBS 
For EV work, media was prepared with heat-inactivated FBS which was free of all 
contaminating EVs. FBS was taken in 40mL centrifuge tubes (Hitachi) and 
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ultracentrifuged at 100,000g using the Himac CP100WX ultracentrifuge (Hitachi) 
for 3 hours at 4ᵒC with a P28S rotor (Hitachi). The supernatant was then taken 
and used to supplement either αMEM or RPMI for treating the MSCs. 
Isolation of MSC-EVs 
MSCs were grown to around 60-70% confluence under standard conditions before 
having their media replaced with 15mL of EV-depleted αMEM16.5%FBS+PS (for 
microvesicle characterization experiments) or RPMI1%FBS+PS (for addition to MDMs 
after preparation). The MSCs were incubated for 48 hours at 37ᵒC and 5%CO2 
and the culture medium was collected. Firstly, the medium was centrifuged at 
10,000g at 4ᵒC for 20 mins to remove cells and cell debris. The supernatant was 
then ultracentrifuged at 100,000g for 2 hours at 4ᵒC and the supernatant was 
aspirated. The pellet of EVs was resuspended in PBS to fill the 40mL tubes before 
centrifuging again at the same settings. This acts as a wash to minimize 
contamination with protein aggregates. The PBS supernatant is then discarded 
and the EV pellet is finally resuspended for downstream processing. 
 
Quantification of MSC-EVs  
In a pilot experiment, MSC-EVs were isolated as described above and the 
concentration of RNA and protein was assessed using the Nanodrop 2000 
(ThermoFisher). Briefly, MSC-EVs were washed and resuspended in 100µL of 
PBS. 1µL of this resuspension was added to the Nanodrop 2000. The RNA 
concentration was found to be 0.47ng/µL corresponding to 47ng of RNA from the 
isolation. The EV isolation had a protein concentration of 1470µg/mL 
corresponding to 147µg of protein in the isolation.  
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Characterization of MSC-EVs by flow cytometry 
To provide an indication of the size of MSC-EVs, MSC-CM was processed by flow 
cytometry with the addition of aldehyde/sulphate latex beads (ThermoFisher) 
which have a diameter of 4µm. The latex beads provide a reference point to 
compare with the EVs in FSC vs SSC plots. MSCs were grown to confluence and 
stained with a number of different reagents. Stains used for the characterization of 
EVs are listed in Table E2. MSCs were treated with human FcR binding inhibitor 
for 20 minutes at 4ºC to prevent non-specific binding. They were stained with 
CellMask™ Orange (cell membrane), propidium iodide (necrosis), Annexin V 
(apoptosis), anti-human CD44 (or isotype control) and MitoTracker® Deep Red 
FM for 45 minutes at 4 ºC in the dark. 
Table E2: Stains used for the characterisation of MSC-EVs 
            Stain        Fluorochrome   
conjugate 
    
Manufacturer 
  CellMask™ Orange                PE ThermoFisher  
    Propidium iodide        PerCP-Cy5.5 Sigma Aldrich 
         Annexin V         Pacific Blue Biolegend        
  Anti-human CD44            PE-Cy7 eBioscience       
MitoTracker® Deep Red 
FM 
             APC ThermoFisher     
 
After the incubation, MSCs were washed three times in PBS and EV-free 
αMEM16.5%FBS+PS was used to prepare CM. After 24 hours, CM was lifted and 
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processed immediately by flow cytometry (FACSCantoII flow cytometer and 
FACSDiva software). Unstained MSC-CM was processed first in order to 
determine the necessary FSC and SSC voltage settings required to detect the 
EVs. Single stain controls were then tested, as well as the isotype for anti-CD44, 
to set gates for these stains and to perform the necessary compensation. The 
gating strategy was as follows: EVs were gated for by FSC vs SSC; cell 
membrane positive events were selected using CellMask™; events which were 
negative for propidium iodide (necrosis) staining were then gated for; Annexin V 
staining (apoptosis) was excluded. This final gate was then used to determine the 
extent of CD44 expression by EVs and the proportion of these EVs which 
contained mitochondria. To provide some information on the size of these EVs, 
latex beads with a diameter of 4µm were processed by flow cytometry first 
separately and then in combination with MSC-CM. FSC vs SSC plots of the latex 
beads provided a reference point to compare with the size of the EVs. 
 
Animal studies 
C57BL/6 male mice (8 to 10 weeks old; Harland Institute, UK) were used. Animals 
were maintained in the Biological Services Unit (BSU) at Queen’s University 
Belfast. Experiments were sanctioned and approved by the UK Home Office and 
Queen’s University Belfast Ethical Review Committee. 
 
Bronchoalveolar lavage (BAL) 
Mice were culled with intraperitoneal (IP) injection of 300µL of xylazine/ketamine 
mixture. The skin of the upper body and neck was cut open and the trachea was 
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exposed. The connective tissue surrounding it was cut away and a length of string 
was placed in behind the trachea. A small hole was cut in the anterior wall of the 
trachea and a severed 21 gauge needle was introduced through the opening. The 
string was then tied around the trachea anchoring the needle in place and 1mL of 
PBS was instilled into the lungs. The PBS was flushed in and lifted out 7-10 times 
to ensure thorough sampling of the bronchoalveolar compartment and to isolate 
as much AMs as possible. 
 
Ex vivo culture of mouse AMs 
A 20µL aliquot of the BALF samples were mixed with 20µL of trypan blue and a 
cell count was performed. Murine AMs were seeded into 6-well plates at 3 million 
per well in the PBS they were extracted in but then spiked with FBS to generate 
PBS1%FBS. The AMs were given 4 hours to adhere before they were gently 
washed with PBS and then treated with MSC-EVs suspended in RPMI1%FBS or 
media alone. For EV-treated AMs, each well was treated with the EVs generated 
from 10 million MSCs over 48 hours. AMs were cultured ex vivo for 48 hours 
before they were detached using 1mL of Accutase® cell detachment reagent 
(Innovative Cell Technologies) incubated for 5 mins at 37ºC. Any cells remaining 
attached were gently dislodged with a cell scraper. The cell viability was 
determined using trypan blue staining and another cell count was performed. The 
cells were then centrifuged at 5000g for 5 mins, the supernatant aspirated and the 
AMs resuspended in PBS such that 35µL of solution contained 2.5x105 AMs.   
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LPS model of lung injury 
Mice were first anaesthetized by isoflurane inhalation for 1-2 minutes individually. 
Mice were given 0.8µg of LPS per gram of body weight. E. coli LPS was 
administered intranasally (IN) diluted in PBS at a volume of 35µL. Control mice 
were given PBS alone. Mice were observed until they recovered from the 
isoflurane. 4 hours after the LPS instillation, mice were anaesthetized once again 
using 100µL of xylazine/ketamine injected using a 25 gauge needle IP. Mice were 
then treated with either vehicle control (PBS), ex vivo-cultured MSC-EV-treated 
AMs or untreated AMs (2.5x105 AMs per mouse) IN in a volume of 35µL. Mice 
were observed until recovery and returned to holding. 24 hours after LPS 
instillation, mice were culled and subjected to BAL to be used for cell counts, 
protein quantification and cytokine analysis. 
 
Total cell counts  
BALF samples were first diluted 2-fold in PBS into fresh eppendorfs, 20µL of this 
was mixed with 20µL of trypan blue and then 10µL of this mixture was added to 
each side of a Countess® cell counting chamber slide (Invitrogen, Thermofisher). 
Total cell counts were carried out using the EVE™ automated cell counter 
(NanoEnTek, VWR). Two counts were taken for each BALF sample and dilutions 
were accounted for in the final cell counts expressed as cells/mL. 
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Cytospin preparation, imaging and neutrophil counts 
After taking the aliquot for total cell counts, BALF samples were centrifuged at 
5000g for 5 mins to remove the cells from suspension. Supernatants were lifted 
and placed in a fresh eppendorf then stored at -20ᵒC for future processing. The 
cell pellet was resuspended in 300µL of PBS and centrifuged at 10,000rpm for 5 
mins using the StatSpin Cytofuge®2 (Beckman Coulter, VWR) onto microscope 
slides. Slides were given 2 hours to dry and then stained using the Speedy Diff kit 
(Clin-tech). Slides were given another hour to dry before imaging using the Leica 
Epifluorescence DM5500 microscope at 20x magnification. Enough images were 
taken of each slide in order to count a total of 400 cells. Cells were counted using 
ImageJ software and the percentage of neutrophils was determined. Using this 
percentage, total neutrophil counts were calculated from the total cell counts taken 
earlier. 
 
RNA isolation 
RNA isolation was carried out using the RNeasy mini kit (Qiagen) as per 
manufacturer’s instructions. After the experiment, MDMs were washed in PBS and 
then 350µL of RLT lysis buffer supplemented with β-mercaptoethanol (inhibits the 
action of RNase enzymes, 10µL per 1mL of lysis buffer) was added to each well. 
To ensure complete lysis of cells, scraped the base of each well using a fresh cell 
scraper and then collected the lysates in a sterile eppendorf. Samples were 
homogenized by passing the solutions through a 25 gauge microneedle 10 times. 
Further processing of RNA was maintained at 4ᵒC throughout. An equal volume of 
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70% ethanol was added to the lysates and the solutions were mixed before 
placing in the spin columns and centrifuging at full speed for 30 seconds. The flow 
through was discarded and 700µL of RW1 buffer was added. Columns were 
centrifuged again and the flow through was aspirated. Next 500µL of RPE buffer, 
supplemented with ethanol, was added and again centrifuged. This RPE buffer 
wash was repeated one more time and then the collection tube holding the spin 
column replaced with a fresh one before centrifuging once again. This step is 
used to ensure that all ethanol has been removed from the columns, as ethanol 
interferes with the final RNA elution step. The spin columns are then placed in a 
final collection eppendorf and 30µL of RNase free water is placed in the column. A 
final centrifugation extracts a pure, concentrated RNA sample.  
 
Quantification of RNA   
Total RNA purity and concentration was determined using the Nanodrop 2000. 
The software was first initialized and then a baseline blank was established by 
placing 1µL of RNase free water on the platform of the device. After setting a 
blank, 1µL of the RNA samples were then added and analyzed. Between sample 
additions, the platform was cleaned using a paper towel soaked with 70% ethanol 
to prevent any sample mixing. Two readings were taken for each sample and an 
average was calculated. A 260/280 purity ratio of 1.8 or higher was considered 
pure enough for downstream processing. Before proceeding to reverse 
transcription, the concentrations of all samples were first normalized to the lowest 
sample concentration of that batch using RNase free water. 
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Real-time qualitative PCR 
RT-PCR was carried out using TaqMan universal PCR master mix along with 
TaqMan primer assay (mRNA) (Thermofisher). PCR reactions were prepared in a 
96 well plate with a total volume of 20µL per reaction: 
Reagent Volume (per reaction) 
Master mix (2X) 10µL 
Primer assay (20X) 1µL 
cDNA diluted in ddH2O 9µL 
 
For every PCR plate prepared, a no template control and a no reverse 
transcription control was included. The no template control contained master mix, 
the primers of interest and only ddH2O. The no reverse transcription control 
contained master mix, primers and an equal amount of RNA which had not been 
converted to cDNA. Each sample was added in duplicate for each assay being 
run. Once the plate had been loaded, the wells were sealed with strip caps, the 
plate was mixed on a shaker for 30 seconds and then centrifuged at 1500rpm for 
2 mins to collect the solutions to the base of each well. The plate was loaded into 
a Stratagene Mx3005P PCR device (Agilent Technologies) and the RT-PCR 
reaction was setup like so: 
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Step number Condition settings Number of cycles 
1 50ᵒC for 2 mins 1 
2 95ᵒC for 10 mins 1 
3 95ᵒC for 15 secs 
60ᵒC for 1 min 
50 
 
Studying mitochondrial transfer 
MSCs were grown to confluence and pre-stained with MitoTracker® Deep Red for 
45 mins at 37ºC before being washed three times with PBS. CM was prepared 
from pre-stained MSCs for 24 hours. MDMs had their nuclei pre-stained with 
Hoechst 33342 (Sigma Aldrich) and their mitochondria pre-stained with 
MitoTracker® Green (Thermofisher) for 45 mins at 37ºC. MDMs were also 
washed with PBS before treating with MSC-CM and incubating the MDMs for 24 
hours to allow EV uptake. MDMs were washed once more with PBS and treated 
with fully supplemented RPMI. Fluorescence imaging of live MDMs was 
performed using the EVOS® FL Auto Imaging System (Life technologies) at 20x 
magnification. 
 
Generating dysfunctional mitochondria 
Loss-of-function experiments were performed to assess the importance of 
mitochondrial transfer from MSCs in their effects on MDMs. In order to produce 
dysfunctional mitochondria, MSCs were treated with rhodamine-6G (Sigma 
Aldrich) at a concentration of 1µg/mL for 48 hours at 37ºC as previously 
described(399). Because mitochondrial respiration would be blocked by this 
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treatment, MSCs had their media supplemented to support glycolysis. Standard α-
MEM16.5%FBS+PS was supplemented further with uridine to produce a concentration 
of 50µg/mL and sodium pyruvate to a concentration of 2.5mM. After 48 hours, 
MSCs were washed three times with PBS before generating CM for experiment. 
To further study the importance of mitochondrial respiration in MDM function, 
MDMs were treated with 3µg/mL of oligomycin which was prepared in DMSO and 
added to RPMI1%FBS+PS. DMSO alone was used as a vehicle control.  
Assessing mitochondrial respiration 
To determine the efficiency of rhodamine-6G as a mitochondrial inhibitor and to 
assess the effect of MSC-CM on MDM mitochondrial activity, the Seahorse XF 
Cell Mito Stress Test Kit (Agilent Technologies) was used. MSCs or MDMs were 
seeded into XF 96-well tissue culture plates at densities of 10,000 and 30,000 
cells per well respectively and allowed to adhere overnight. The cells were then 
treated with the various conditions for 24-48 hours depending on the experiment. 
During this incubation a cartridge plate provided with the kit, which contained the 
probes for measuring oxygen consumption, was soaked in XF calibrant solution 
and left to incubate at 37ºC and 0% CO2. Cells were washed twice with XF basal 
medium which had been supplemented with 10mM glucose, 1mM pyruvate and 
2mM glutamine. 180µL of XF basal medium was added to each well and the cells 
were placed in the incubator at 37ºC and 0% CO2 for 1 hour. Meanwhile the 
oligomycin, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) and 
rotenone/antimycin-A inhibitors were prepared as per the manufacturer’s 
instructions. The probe cartridge was collected from the incubator and the 
inhibitors were added to specific ports of these cartridges. 20µL of oligomycin was 
added to port A, 22µL of FCCP was added to port B and 25µL of 
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rotenone/antimycin-A was added to port C for each well. These inhibitors would 
be sequentially injected into the cell solution during the Mito Stress Test. The 
loaded cartridge plate was then placed in the XFe96 Extracellular Flux Analyser 
(Agilent Technologies) for calibration. After calibration, the XF 96-well tissue 
culture plate containing the cells was added to the machine and the Mito Stress 
Test was performed. Oxygen consumption rate readouts produced by the assay 
were analyzed using the Wave software (Version 2.2) (Agilent Technologies). 
Lactate dehydrogenase (LDH) assay  
For pilot ARDS patient BALF, oligomycin and rhodamine-6G stimulation 
experiments, cytotoxicity assays were performed on the hMDMs or hMSCs using 
the Cytotoxicity Detection Kit (LDH) (Life Sciences, Roche). After treatment the 
supernatants were lifted and cell debris was removed by centrifugation at 500G 
for 10 mins. 50µL of each sample was added in duplicate to wells of a Maxisorp 
96-well ELISA plate (Nunc). Assay mixture was prepared by mixing 250µL of the 
diaphorase/NAD+ catalyst with 11.25mL of the iodotetrazolium chloride/sodium 
lactate dye solution. 50µL of the assay mixture was added to each well on top of 
the samples and mixed on a shaker for 1 minute. The assay mixture is pink and 
will turn red as the assay develops. The 96-well plate was then incubated at room 
temperature for 30 mins before being read by a spectrophotometer at 490nm. A 
number of controls are included for this assay; a background control is 100µL of 
the assay mixture and is used as a blank which is subtracted from all other values. 
There is an untreated control of hMDMs cultured in RPMI1%FBS+PS alone to 
determine basal LDH release. Then there is the cell death control which consisted 
of RPMI1%FBS+PS with 2% Triton-X detergent (Sigma Aldrich) to induce total cell 
death. Cell death was calculated as a percentage relative to the cell death control. 
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Absorbance readings of the background control were subtracted from all other 
readings. Then the following calculation was used for the test conditions: 
Cytotoxicity (%) = (experimental value/cell death control value) x 100 
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SUPPLEMENTAL FIGURE LEGEND 
Figure E1. Fibroblasts in non-contact co-culture do not mimic the macrophage 
modulation effects of mesenchymal stromal cells (MSCs) in the presence of 
lipopolysaccharide (LPS). Fibroblasts are able to reduce TNF-α production by 
LPS-treated monocyte-derived macrophages (MDMs) (A) but have no effect on IL-
8 production (B) (n=3 per group). Fibroblasts do not increase the expression of 
M2 macrophage marker CD206 (C) (n=4 per group). All one-way ANOVA with 
Bonferroni’s post-hoc test. Data are presented as mean ± standard deviation. 
 
Figure E2. Mesenchymal stromal cells (MSCs) have no effect on total IL-8 levels 
in bronchoalveolar lavage fluid (BALF)-treated monocyte-derived macrophages 
(MDMs) (n=2 per group). Data are presented as mean ± standard deviation. 
 
Figure E3. Rhodamine-6G pre-treatment of human mesenchymal stromal cells 
(MSCs) inhibits mitochondrial function and has little effect on paracrine factor 
production. (A) After 48 hours of rhodamine pre-treatment, MSCs had dramatically 
reduced maximal mitochondrial respiratory capacity (i) and mitochondrial ATP 
turnover (ii), resulting in upregulation of non-mitochondrial respiration (iii) 
demonstrated by the Seahorse metabolic analyzer (n=1 (in triplicate) per group). 
Rhodamine pre-treatment resulted in a small reduction in the levels of 
angiopoietin-1 (B) and IL-8 (C) in MSC culture medium (n=2 (in triplicate) per 
group). Rhodamine treatment of MSCs had no cytotoxic effects at 48 hours (D) 
(n=1 per group). Data are presented as mean ± standard deviation. 
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Figure E4. Oligomycin treatment for 24 hours does not have cytotoxic effects on 
monocyte-derived macrophages (MDMs) (n=2 per group). Data are presented as 
mean ± standard deviation. 
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